Earlier this month, the FDA approved Bildyos and Bilprevda (denosumab-nxxp), 2 additional denosumab biosimilars for Prolia and Xgeva, respectively. 2 In March 2025, the FDA approved the biosimilars ...
The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Prolia (denosumab) is a prescription drug that’s used to treat osteoporosis and bone loss. Prolia comes as a liquid solution that’s given as an injection under the skin. Prolia is prescribed for ...
USFDA approved affordable biosimilars Bosaya and Aukelso approved by Biocon Biologics Ltd, offering treatment options for ...
The Food and Drug Administration (FDA) has approved Bosaya ™ (denosumab-kyqq) and Aukelso ™ (denosumab-kyqq), biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively.
THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare ...
SHANGHAI, Sept. 5, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, ...
Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...
Biocon Biologics has secured USFDA approval for denosumab biosimilars Bosaya and Aukelso, with provisional interchangeability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback